Cancer genomics: From discovery science to personalized medicine

Nature Medicine

Volumn 17, Issue 3, 2011, Pages 297-303

  Chin, Lynda ^a,b,c   Andersen, Jannik N ^a   Futreal, P Andrew ^d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE INHIBITOR; BCR ABL PROTEIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GLUTAMIC ACID; GLYCINE; H RAS PROTEIN; IMATINIB; INCB 018424; INIPARIB; ISOCITRATE DEHYDROGENASE; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MK 4827; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PANITUMUMAB; PLX 4032; PROTEIN N RAS; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALINE;

AMINO ACID SUBSTITUTION; BREAST CANCER; CANCER GENETICS; CANCER PREVENTION; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DRUG RESEARCH; DRUG TARGETING; EARLY DIAGNOSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE TECHNOLOGY; GENETIC ANALYSIS; GLIOBLASTOMA; HIGH THROUGHPUT SCREENING; HUMAN; IDH1 GENE; IDH2 GENE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MYELOFIBROSIS; ONCOGENE; ONCOGENE C H RAS; ONCOGENE K RAS; ONCOGENE N RAS; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SEQUENCE ANALYSIS; TUMOR GENE;

GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS;

EID: 79952395270     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2323     Document Type: Review

References (68)

1. Reddy, E.P., Reynold, R.K., Santos, E. & Barbacid, M. A point mutation is responsible for the acquisition of transforming properties of the T24 human bladder carcinoma oncogene. Nature 300, 149-152 (1982). (Pubitemid 12006347)
2. Tabin, C.J. Mechanism of activation of a human oncogene. Nature 300, 143-149 (1982). (Pubitemid 12006346)
3. Capon, D.J. et al. Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutations. Nature 304, 507-513 (1983). (Pubitemid 13026946)
4. McGrath, J.P. et al. Structure and organization of the human Ki-ras proto-oncogene and a related processed pseudogene. Nature 304, 501-506 (1983). (Pubitemid 13026945)
5. Shimizu, K. et al. Structure of the Ki-ras gene of the human lung carcinoma cell line Calu-1. Nature 304, 497-500 (1983). (Pubitemid 13026944)
6. Bos, J.L. et al. Amino-acid substitutions at codon 13 of the N-ras oncogene in human acute myeloid leukaemia. Nature 315, 726-730 (1985). (Pubitemid 15022925)
7. Downward, J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3, 11-22 (2003). (Pubitemid 37328883)
8. Sousa, S.F., Fernandes, P.A. & Ramos, M.J. Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem. Curr. Med. Chem. 15, 1478-1492 (2008). (Pubitemid 351997780)
9. Haura, E.B. et al. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin. Cancer Res. 16, 2450-2457 (2010)
10. Allegra, C.J. et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 27, 2091-2096 (2009).
11. Lièvre, A. et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26, 374-379 (2008). (Pubitemid 351171687)
12. Amado, R.G. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 1626-1634 (2008).
13. Eberhard, D.A. et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23, 5900-5909 (2005).
14. Futreal, P.A. et al. A census of human cancer genes. Nat. Rev. Cancer 4, 177-183 (2004). (Pubitemid 38337497)
15. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002). (Pubitemid 34716871)
16. Flaherty, K.T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010).
17. Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 504-508, (2004).
18. Bachman, K.E. A.P., Samuels, Y., Silliman, N., Ptak, J., Szabo, S., Konishi, H., Karakas, B., Blair, B.G., Lin, C., Peters, A.B., Velculescu, V.E. & Park, B.H. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther. 3, 772-775 (2004). (Pubitemid 41351083)
19. Campbell, I.G. et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64, 7678-7681 (2004). (Pubitemid 39446895)
20. Brachmann, S., Fritsch, C., Maira, S.-M. & García- Echeverría, C. PI3K and mTOR inhibitors- a new generation of targeted anticancer agents. Curr. Opin. Cell Biol. 21, 194-198 (2009).
21. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
22. Jaiswal, B.S. et al. Somatic mutations in p85α promote tumorigenesis through class IA PI3K activation. Cancer Cell 16, 463-474 (2009).
23. Zhao, L. & Vogt, P.K. Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl. Acad. Sci. USA 105, 2652-2657 (2008). (Pubitemid 351520568)
24. Turke, A.B. & Engelman, J.A. PIKing the right patient. Clin. Cancer Res. 16, 3523-3525 (2010).
25. Courtney, K.D., Corcoran, R.B. & Engelman, J.A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 28, 1075-1083 (2010).
26. Kralovics, R. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779-1790 (2005). (Pubitemid 40570926)
27. Levine, R.L. et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7, 387-397 (2005). (Pubitemid 40544655)
28. Verstovsek, S. et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N. Engl. J. Med. 363, 1117-1127 (2010).
29. Curtin, J.A., Busam, K., Pinkel, D. & Bastian, B.C. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 24, 4340-4346 (2006). (Pubitemid 46630793)
30. Dutt, A. et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc. Natl. Acad. Sci. USA 105, 8713-8717 (2008). (Pubitemid 351987745)
31. Pollock, P.M. et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 26, 7158-7162 (2007). (Pubitemid 350059681)
32. Handolias, D. et al. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. Br. J. Cancer 102, 1219-1223 (2010).
33. Van Raamsdonk, C.D. et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457, 599-602 (2009).
34. Stephens, P. et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431, 525-526 (2004).
35. Slamon, D.J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001). (Pubitemid 32222155)
36. Lynch, T.J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004). (Pubitemid 38637993)
37. Parsons, D.W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812 (2008).
38. Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765-773 (2009).
39. Reitman, Z.J. & Yan, H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J. Natl. Cancer Inst. 102, 932-941 (2010).
40. Dalgliesh, G.L. et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463, 360-363 (2010).
41. van Haaften, G. et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat. Genet. 41, 521-523 (2009).
42. Jones, S., et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330, 228-231 (2010).
43. Wiegand, K.C., et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N. Engl. J. Med. 363, 1532-1543 (2010).
44. Varela, I. et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469, 539-542 (2011).
45. Fong, P.C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. J. Clin. Oncol. 28, 2512-2519 (2010).
46. Fong, P.C. et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol. 28, 2512-2519 (2010).
47. Mendes-Pereira, A.M. et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 1, 315-322 (2009).
48. McEllin, B. et al. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res. 70, 5457-5464 (2010).
49. Shen, W.H. et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128, 157-170 (2007). (Pubitemid 46048887)
50. The International Cancer Genome Consortium. International network of cancer genome projects. Nature 464, 993-998 (2010).
51. Chen, Y. et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455, 971-974 (2008).
52. Janoueix-Lerosey, I. et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455, 967-970 (2008).
53. Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566 (2007). (Pubitemid 47206930)
54. Tomlins, S.A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648 (2005). (Pubitemid 41528150)
55. Chin, L. & Gray, J.W. Translating insights from the cancer genome into clinical practice. Nature 452, 553-563 (2008). (Pubitemid 351483369)
56. Verhaak, R.G.W. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98-110 (2010).
57. Chin, L. et al. Essential role for oncogenic Ras in tumour maintenance. Nature 400, 468-472 (1999). (Pubitemid 29361802)
58. Kwong, L.N. & Chin, L. The brothers RAF. Cell 140, 180-182 (2010).
59. Shaw, A.T. et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 27, 4247-4253 (2009).
60. Koivunen, J.P. et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res. 14, 4275-4283 (2008).
61. Soda, M. et al. A mouse model for EML4-ALK-positive lung cancer. Proc. Natl. Acad. Sci. USA 105, 19893-19897 (2008).
62. McDermott, U. et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 68, 3389-3395 (2008).
63. Kwak, E.L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
64. Dierks, C. et al. The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease. Cancer Res. 70, 6193-6204 (2010).
65. Pechloff, K. et al. The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma. J. Exp. Med. 207, 1031-1044 (2010).
66. Riccaboni, M., Bianchi, I. & Petrillo, P. Spleen tyrosine kinases: biology, therapeutic targets and drugs. Drug Discov. Today 15, 517-530 (2010).
67. Uckun, F.M., Ek, R.O., Jan, S.T., Chen, C.L. & Qazi, S. Targeting SYK kinase-dependent anti-apoptotic resistance pathway in B-lineage acute lymphoblastic leukaemia (ALL) cells with a potent SYK inhibitory pentapeptide mimic. Br. J. Haematol. 149, 508-517 (2010).
68. Kwitkowski, V.E. et al. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Oncologist 15, 428-435 (2010).